Printer Friendly

ISIS PHARMACEUTICALS ACQUIRES RIGHTS TO 'PEPTIDE NUCLEIC ACID' TECHNOLOGY

 ISIS PHARMACEUTICALS ACQUIRES RIGHTS TO 'PEPTIDE NUCLEIC ACID'
 TECHNOLOGY
 CARLSBAD, Calif., April 20 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) today announced the signing of a research and license agreement with investigators at the Panum Institute (the Orsted Institute) of the University of Copenhagen and Riso National Laboratory dealing with the group's "Peptide Nucleic Acid" (PNA) technology. Preliminary data on these "peptide-like nucleic acids" were published by Dr. Peter Nielsen, Dr. Michael Egholm, Dr. Rolf Berg and Dr. Ole Buchardt, in the Dec. 6, 1991, issue of Science magazine. This recently signed agreement grants Isis the exclusive worldwide rights to make and use PNA oligomers for therapeutic uses.
 "The initial data suggests that PNA oligomers will bind more tightly to target RNA or DNA than oligonucleotides with other known backbone structures yielding potentially greater potency," said Christopher Mirabelli, Ph.D. senior vice president of research and preclinical development at Isis. "This work, together with important proprietary oligonucleotide backbone structures discovered by Isis scientists, puts us in an extremely strong position to identify and develop pharmaceutical products that are superior to any existing type of oligonucleotide."
 Under the terms of the agreement, Isis and the Copenhagen group will also work collaboratively on the medicinal chemistry and scale-up of PNA oligomers.
 "We are very pleased to have gained access to this exciting new technology and we plan to pursue its incorporation into drugs very aggressively," added Dr. Daniel Kisner, executive vice president.
 Located in northern San Diego, Isis is engaged in the discovery, development and marketing of novel human therapeutic products based on antisense oligonucleotides. Isis recently received approval by the FDA to begin clinical trials on a new drug, the first antisense drug to be administered to humans for the treatment of human papillomavirus.
 -0- 4/20/92
 /CONTACT: Daniel L. Kisner of Isis Pharmaceuticals, 619-931-9200, or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
 (ISIP) CO: Isis Pharmaceuticals Inc. ST: California IN: MTC SU: TNM


SH-TS -- NY014 -- 9922 04/20/92 09:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1992
Words:336
Previous Article:PLASMA-THERM ANNOUNCES FIRST QUARTER 1992 RESULTS
Next Article:ALAMO JUMP STARTS SLUGGISH CAR RENTAL MARKET WITH LOWEST RATE ON A LUXURY CAR EVER SEEN IN INDUSTRY


Related Articles
ISIS PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
ISIS PHARMACEUTICALS AND COLLABORATORS ANNOUNCE FINDINGS ON PNA, A NOVEL DNA BACKBONE FOR A NEW GENERATION OF ANTISENSE DRUGS
DR. KANDA RAMASAMY JOINS VIRATEK AS SENIOR SCIENTIST AND HEAD OF OLIGONUCLEOTIDE CHEMISTRY
Isis Sublicences PNA Technology Patent to Pantheco A/S to Develop Anti-Infective Agents.
Isis sublicences peptide nucleic acid technology patent to Pantheco to develop anti-Infective agents.
Isis Pharmaceuticals Broadens Licensing of Third-Generation Antisense Chemistry to Pantheco A/S for $1.1 Million License Fee.
IBC's Annual TIDES(R) 2003 Reflects Exciting Developments: Agenda Available Online.
Isis to Receive $26.5 Million from Alnylam.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters